2021 ICD-10-CM Diagnosis Code C7B.8

Other secondary neuroendocrine tumors

    2016 2017 2018 2019 2020 2021 Billable/Specific Code
  • C7B.8 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
  • The 2021 edition of ICD-10-CM C7B.8 became effective on October 1, 2020.
  • This is the American ICD-10-CM version of C7B.8 - other international versions of ICD-10 C7B.8 may differ.
The following code(s) above C7B.8 contain annotation back-references
Annotation Back-References
In this context, annotation back-references refer to codes that contain:
  • Applicable To annotations, or
  • Code Also annotations, or
  • Code First annotations, or
  • Excludes1 annotations, or
  • Excludes2 annotations, or
  • Includes annotations, or
  • Note annotations, or
  • Use Additional annotations
that may be applicable to C7B.8:
  • C00-D49
    2021 ICD-10-CM Range C00-D49

    Neoplasms

    Note
    • Functional activity
    • All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
    • Morphology [Histology]
    • Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
    • Primary malignant neoplasms overlapping site boundaries
    • A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
    • Malignant neoplasm of ectopic tissue
    • Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
    Neoplasms
  • C7B
    ICD-10-CM Diagnosis Code C7B

    Secondary neuroendocrine tumors

      2016 2017 2018 2019 2020 2021 Non-Billable/Non-Specific Code
    Use Additional
    • code to identify any functional activity
    Secondary neuroendocrine tumors
Approximate Synonyms
  • Cancer metastatic to abdomen
  • Cancer metastatic to lung
  • Cancer metastatic to mediastinum
  • Neuroendocrine carcinoma metastatic to bilateral lungs
  • Neuroendocrine carcinoma metastatic to left lung
  • Neuroendocrine carcinoma metastatic to right lung
  • Neuroendocrine tumor metastatic to dist lymph node
  • Neuroendocrine tumor, metastatic
  • Neuroendocrine tumor, metastatic to bone
  • Neuroendocrine tumor, metastatic to liver
  • Neuroendocrine tumor, metastatic to peritoneum
  • Secondary neuroendocrine carcinoma of abdomen
  • Secondary neuroendocrine carcinoma of bilateral lungs
  • Secondary neuroendocrine carcinoma of bone
  • Secondary neuroendocrine carcinoma of left lung
  • Secondary neuroendocrine carcinoma of liver
  • Secondary neuroendocrine carcinoma of lung
  • Secondary neuroendocrine carcinoma of lymph node
  • Secondary neuroendocrine carcinoma of mediastinum
  • Secondary neuroendocrine carcinoma of peritoneum
  • Secondary neuroendocrine carcinoma of right lung
  • Secondary neuroendocrine carcinoma of unspecified site
ICD-10-CM C7B.8 is grouped within Diagnostic Related Group(s) (MS-DRG v38.0):
  • 826 Myeloproliferative disorders or poorly differentiated neoplasms with major o.r. Procedures with mcc
  • 827 Myeloproliferative disorders or poorly differentiated neoplasms with major o.r. Procedures with cc
  • 828 Myeloproliferative disorders or poorly differentiated neoplasms with major o.r. Procedures without cc/mcc
  • 829 Myeloproliferative disorders or poorly differentiated neoplasms with other procedures with cc/mcc
  • 830 Myeloproliferative disorders or poorly differentiated neoplasms with other procedures without cc/mcc
  • 843 Other myeloproliferative disorders or poorly differentiated neoplastic diagnoses with mcc
  • 844 Other myeloproliferative disorders or poorly differentiated neoplastic diagnoses with cc
  • 845 Other myeloproliferative disorders or poorly differentiated neoplastic diagnoses without cc/mcc

Convert C7B.8 to ICD-9-CM

Code History
  • 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
  • 2017 (effective 10/1/2016): No change
  • 2018 (effective 10/1/2017): No change
  • 2019 (effective 10/1/2018): No change
  • 2020 (effective 10/1/2019): No change
  • 2021 (effective 10/1/2020): No change

Diagnosis Index entries containing back-references to C7B.8:

ICD-10-CM Codes Adjacent To C7B.8
C7A.8 Other malignant neuroendocrine tumors
C7B Secondary neuroendocrine tumors
C7B.0 Secondary carcinoid tumors
C7B.00 …… unspecified site
C7B.01 …… of distant lymph nodes
C7B.02 …… of liver
C7B.03 …… of bone
C7B.04 …… of peritoneum
C7B.09 …… of other sites
C7B.1 Secondary Merkel cell carcinoma
C7B.8 Other secondary neuroendocrine tumors
C76 Malignant neoplasm of other and ill-defined sites
C76.0 Malignant neoplasm of head, face and neck
C76.1 Malignant neoplasm of thorax
C76.2 Malignant neoplasm of abdomen
C76.3 Malignant neoplasm of pelvis
C76.4 Malignant neoplasm of upper limb
C76.40 Malignant neoplasm of unspecified upper limb
C76.41 Malignant neoplasm of right upper limb
C76.42 Malignant neoplasm of left upper limb
C76.5 Malignant neoplasm of lower limb

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.